- Home
- NXL
as 12-18-2024 2:40pm EST
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 10.0M | IPO Year: | 2022 |
| Target Price: | N/A | AVG Volume (30 days): | 533.6K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.67 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $4.49 | Next Earning Date: | 11-08-2024 |
| Revenue: | $162,078 | Revenue Growth: | 26.00% |
| Revenue Growth (this year): | 56.86% | Revenue Growth (next year): | 167.44% |
Latest Nexalin Technology Inc. News
NXL Breaking Stock News: Dive into NXL Ticker-Specific Updates for Smart Investing
GlobeNewswire
22 days ago
New Peer-Reviewed Publication Validates Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Technology, Reinforcing Leadership in High-Growth Neuromodulation Market
GlobeNewswire
a month ago
Nexalin Technology CEO Provides Letter to Shareholders
Simply Wall St.
a month ago
Is Nexalin Technology (NASDAQ:NXL) In A Good Position To Invest In Growth?
GlobeNewswire
2 months ago
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
MT Newswires
2 months ago
Nexalin Technology Regains Nasdaq Compliance Over Minimum Bid Price; Shares Rise
GlobeNewswire
2 months ago
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
ACCESSWIRE
2 months ago
LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
2 months ago
Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
Compare NXL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NXL Nexalin Technology Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.